Ljerka Delac

Ljerka Delac

Auto-generated profile, based on publicly available information

Ljerka Delac

Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society Karolinska Institutet Solna Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in Science Advances
Verified
Journal Article
Open access
MLMaría Latorre-Leal
María Latorre-Leal
PRPatricia Rodriguez-Rodriguez
Patricia Rodriguez-Rodriguez
LFLuca Franchini
Luca Franchini
ONOrestis Nikolidakis
Orestis Nikolidakis
MDMakrina Daniilidou
Makrina Daniilidou
SMSilvia Maioli
Silvia Maioli
The brain-specific enzyme CYP46A1 controls cholesterol turnover by converting cholesterol into 24 S -hydroxycholesterol (24OH). Dysregulation of brain cholesterol turnover and reduced CYP46A1 levels are observed in Alzheimer’s disease (AD). In this study, we report that CYP46A1 overexpression in aged female mice leads to enhanced estrogen signaling in the hippocampus and improved cognitive functions. In contrast, age-matched CYP46A1 overexpressing males show anxiety-like behavior, worsened memory, and elevated levels of 5α-dihydrotestosterone in the hippocampus. We report that, in neurons, 24OH contributes to these divergent effects by activating sex hormone signaling, including estrogen receptors. CYP46A1 overexpression in female mice protects from memory impairments induced by ovariectomy while having no effects in gonadectomized males. Last, we measured cerebrospinal fluid levels of 24OH in a clinical cohort of patients with AD and found that 24OH negatively correlates with neurodegeneration markers only in women. We suggest that CYP46A1 activation is a valuable pharmacological target for enhancing estrogen signaling in women at risk of developing neurodegenerative diseases.

6 November 2025 in Journal of Lipid Research
Verified
Journal Article
Open access
MDMichelle Dunk
Michelle Dunk
LDLjerka Delac
Ljerka Delac
SRStephen R. Rapp
Stephen R. Rapp
IDIra Driscoll
Ira Driscoll
MLMaria Latorre-Leal
Maria Latorre-Leal
SMSilvia Maioli
Silvia Maioli
Women face a higher lifetime risk of developing neurodegenerative diseases such as Alzheimer's disease (AD) and related dementia (ADRD). The menopausal transition, characterized by a decline in estrogen levels, may affect cholesterol metabolism and neurodegenerative processes. Oxysterols, oxidized cholesterol derivatives, play a role in these pathways, with 24(S)-hydroxycholesterol (24HC) reflecting brain cholesterol turnover and 27-hydroxycholesterol (27HC) linked to systemic cholesterol metabolism. We investigated associations of plasma oxysterols with circulating sex hormones and characteristics of reproductive history in 1,974 postmenopausal women with no history of dementia from the Women's Health Initiative, taking into account APOE4 status and cholesterol-lowering medication. We found that higher levels of bioavailable estradiol were associated with higher 24HC and 27HC levels, and higher estrone was associated with higher 24HC (all p-values < 0.05). Associations of estradiol with 24HC and 27HC were stronger among those not using cholesterol medication and APOE4 carriers, with a significant interaction between 27HC and APOE4 in relation to 27HC (p for interaction = 0.04). Having an older age at menopause was associated with lower 24HC among those taking cholesterol medication (p for interaction = 0.03). Our findings suggest that 24HC and 27HC may be proxy biomarkers of neuronal health and estrogen status in postmenopausal women. The stronger associations between estradiol and oxysterols among APOE4 carriers and those not using cholesterol-lowering medication suggest the need to account for hormonal, genetic, and pharmacological factors when evaluating neurodegenerative risk. Longitudinal studies are warranted to further investigate oxysterols as potential early biomarkers of ADRD risk.

20 November 2023 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
DRDaniel Rehlicki
Daniel Rehlicki
MPMia Plenkovic
Mia Plenkovic
LDLjerka Delac
Ljerka Delac
DPDawid Pieper
Dawid Pieper
AMAna Marušić
Ana Marušić
LPLivia Puljak
Livia Puljak

17 October 2025 in Current Opinion in Endocrine and Metabolic Research
Verified
Journal Article
Open access
LDLjerka Delac
Ljerka Delac
SMSilvia Maioli
Silvia Maioli

11 March 2026 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
PDF file
PMPatricia Muñoz
Patricia Muñoz
HAHeba G. Ali
Heba G. Ali
ADAphrodite Demetriou
Aphrodite Demetriou
MLMaria Latorre‐Leal
Maria Latorre‐Leal
MSMakoto Shimozawa
Makoto Shimozawa
Ivan NalvarteIvan Nalvarte
Ivan Nalvarte
More women than men are diagnosed with Alzheimer's disease (AD). Sex hormones have been ascribed neuroprotective properties, and their decline, particularly the reduction of estrogen during menopause, has been implicated in AD risk. In this study, we examined how loss of circulating sex hormones affects cognitive performance and amyloid pathology in two mouse models of AD, the aggressive App NL‐G‐F and the slower App NL‐F models of brain amyloidosis. Bilateral gonadectomy was induced in both male and female App NL‐G‐F and App NL‐F mice. Pathology was assessed using cognitive tests and histological evaluations of amyloid depositions and neuroinflammation. Serum and brain estrogen and testosterone levels were measured by ELISA, and the expression of key estrogenic signaling genes was evaluated using qPCR. We report that female gonadectomy had little impact on behavior or pathology in the App NL‐G‐F model, whereas male gonadectomy improved learning and reduced hippocampal amyloid depositions. In the App NL‐F model, gonadectomy worsened amyloid pathology in both sexes. Hormone analysis revealed that significant levels of estrogen in females, but not testosterone in males, remain partly preserved in the brain after gonadectomy, and that low testosterone levels associate with increased insulin‐like growth factor 1 (IGF‐1) expression which may play a compensatory role in maintaining estrogenic signaling. Our study provides new insights into how the loss of circulating sex hormones influences brain sex hormone levels and AD pathology and contributes to a better understanding of the sex differences observed in this disease.